{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-076382","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.743038+00:00","generated_at":"2026-06-01T00:33:27.591055+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"low","headline":"Rezolute releases Phase 2 topline results for RZ402 in DME; no specifics in filing","bullets":["Topline results from Phase 2 study of RZ402 in diabetic macular edema (DME) disclosed via website and SEC filing on June 28, 2024.","Presentation originally provided during May 21, 2024 investor webcast; appendix added on June 28, 2024.","Actual efficacy or safety data (e.g., p-values, responder rates) are not visible in the available 8-K or exhibit text."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-076382","json":"https://secwatch.observer/filing/0001104659-24-076382.json","markdown":"https://secwatch.observer/filing/0001104659-24-076382.md","text":"https://secwatch.observer/filing/0001104659-24-076382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924076382/0001104659-24-076382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924076382/tm2418270d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:33:27.591055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}